CSS LLC’s Krystal Biotech KRYS Stock Holding History

CSS LLC’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-300	Closed	-$16K	–	1283
2021 Q3	$16K	Buy	+300	New	+$17.8K	﹤0.01%	1138

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CSS LLC's KRYS Position: Q4 2021 in Review

CSS LLC sold out of Krystal Biotech (KRYS) in Q4 2021, closing a stake of 300 shares — an estimated $16K sold.

CSS LLC first reported a position in KRYS in Q3 2021 and held it in 1 quarter. The position peaked at $16K in Q3 2021. 140 funds tracked by Wall St. Rank hold KRYS as of Q4 2021.

CSS LLC reported no remaining Krystal Biotech position as of Q4 2021 after selling out during the quarter.
CSS LLC sold 300 Krystal Biotech shares in Q4 2021, an estimated $16K.
CSS LLC first reported a position in Krystal Biotech in Q3 2021 and held it in 1 quarter.
CSS LLC's Krystal Biotech position peaked at $16K in Q3 2021.
140 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2021.

Based on CSS LLC's 13F filing for Q4 2021, filed 14 Feb 2022.